This research service analyzes the changing dynamics in the U.S. anticoagulant market for the period 2002-2012. Included are pipeline analysis, and individual segment revenue forecasts as well as selected major products. Both products currently in the market, as well as those forecast to enter the market by 2012 are included, with an emphasis on branded drug products. The market is segmented by product class: warfarin, heparins, direct thrombin inhibitors, synthetic pentasaccharides, and emerging anticoagulant products. The products covered in this research service are used in the treatment of diseases such as acute coronary syndromes, venous thromboembolism, stroke, and atrial fibrillation.